BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biomatter Raises $18 Million to Accelerate AI-Designed Enzymes From Lab to Market

AstraZeneca, BASF, and Sanofi among 25+ enterprise customers, with more than 50 custom enzymes delivered Proceeds will grow the commercial team and US p...

November 13, 2026 | News

Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Monthly GLP-1 Programme

Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist Pfizer Inc. (NYSE: PFE) and Blackstone...

November 13, 2026 | News

Sino Biological Introduces 4RISE to Accelerate Validation of AI-Designed Proteins

Faster Expression. Deeper Validation. Integrated Support. AI can generate protein candidates at an unprecedented speed, but experimental validation remain...

November 12, 2026 | News

Abbisko’s PIMJETMI Secures FDA Approval for Symptomatic Tenosynovial Giant Cell Tumour

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), dem...

November 12, 2026 | News

Neobe Therapeutics Raises US$6.8 Million to Advance Engineered Bacteria for Solid Tumours

Neobe has secured a seed round of US$6.8 million (£5 million) to accelerate the development of engineered bacteria that break down the physical...

November 11, 2026 | News

Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery

Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...

November 11, 2026 | News

Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...

November 11, 2026 | News

Ribo Files EU Phase I Trial Application for Dual-Target siRNA Therapy SR122

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase...

November 11, 2026 | News

Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...

November 10, 2026 | News

China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

November 09, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

Illumina Selected to Sequence 450,000 Genomes for Singapore’s SG-INSIGHT Study

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be i...

November 06, 2026 | News

Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer

Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...

November 06, 2026 | News

Telix Joins Thera4Care to Advance FAP-Targeted Theranostics Research

Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix's fibroblast activation...

November 06, 2026 | News

Stay Connected